company background image
0O5H logo

Elekta LSE:0O5H Stock Report

Last Price

kr80.68

Market Cap

kr30.8b

7D

1.6%

1Y

3.4%

Updated

26 Mar, 2024

Data

Company Financials +

0O5H Stock Overview

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide.

0O5H fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends4/6

Elekta AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Elekta
Historical stock prices
Current Share Pricekr80.68
52 Week Highkr90.40
52 Week Lowkr71.30
Beta1.01
1 Month Change8.42%
3 Month Change-0.99%
1 Year Change3.39%
3 Year Change-27.93%
5 Year Change-28.51%
Change since IPO178.58%

Recent News & Updates

Recent updates

Shareholder Returns

0O5HGB Medical EquipmentGB Market
7D1.6%-2.1%2.1%
1Y3.4%0.8%3.8%

Return vs Industry: 0O5H exceeded the UK Medical Equipment industry which returned 0.8% over the past year.

Return vs Market: 0O5H matched the UK Market which returned 3.8% over the past year.

Price Volatility

Is 0O5H's price volatile compared to industry and market?
0O5H volatility
0O5H Average Weekly Movement3.3%
Medical Equipment Industry Average Movement7.6%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0O5H has not had significant price volatility in the past 3 months.

Volatility Over Time: 0O5H's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19724,584Gustaf Salfordhttps://elekta.com

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care.

Elekta AB (publ) Fundamentals Summary

How do Elekta's earnings and revenue compare to its market cap?
0O5H fundamental statistics
Market capkr30.83b
Earnings (TTM)kr1.43b
Revenue (TTM)kr18.22b

21.5x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0O5H income statement (TTM)
Revenuekr18.22b
Cost of Revenuekr11.32b
Gross Profitkr6.90b
Other Expenseskr5.47b
Earningskr1.43b

Last Reported Earnings

Jan 31, 2024

Next Earnings Date

Jun 05, 2024

Earnings per share (EPS)3.75
Gross Margin37.88%
Net Profit Margin7.86%
Debt/Equity Ratio57.2%

How did 0O5H perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

64%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.